EP4077311A4 - Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents

Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen Download PDF

Info

Publication number
EP4077311A4
EP4077311A4 EP20901675.7A EP20901675A EP4077311A4 EP 4077311 A4 EP4077311 A4 EP 4077311A4 EP 20901675 A EP20901675 A EP 20901675A EP 4077311 A4 EP4077311 A4 EP 4077311A4
Authority
EP
European Patent Office
Prior art keywords
preparation methods
heterocyclic compounds
heterocyclic
compounds
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20901675.7A
Other languages
English (en)
French (fr)
Other versions
EP4077311A1 (de
Inventor
Xing DAI
Yueheng Jiang
Yanqin Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inventisbio Co Ltd
Original Assignee
Inventisbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Co Ltd filed Critical Inventisbio Co Ltd
Publication of EP4077311A1 publication Critical patent/EP4077311A1/de
Publication of EP4077311A4 publication Critical patent/EP4077311A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP20901675.7A 2019-12-18 2020-12-17 Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen Pending EP4077311A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/126230 WO2021120045A1 (en) 2019-12-18 2019-12-18 Heterocyclic compounds, preparation methods and uses thereof
PCT/CN2020/137276 WO2021121330A1 (en) 2019-12-18 2020-12-17 Heterocyclic compounds, preparation methods and uses thereof

Publications (2)

Publication Number Publication Date
EP4077311A1 EP4077311A1 (de) 2022-10-26
EP4077311A4 true EP4077311A4 (de) 2023-11-22

Family

ID=76476909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20901675.7A Pending EP4077311A4 (de) 2019-12-18 2020-12-17 Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen

Country Status (8)

Country Link
US (3) US11241437B2 (de)
EP (1) EP4077311A4 (de)
JP (1) JP2023506308A (de)
KR (1) KR20220118478A (de)
CN (2) CN118459459A (de)
AU (1) AU2020410474A1 (de)
CA (1) CA3161852A1 (de)
WO (2) WO2021120045A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
JP2022548791A (ja) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022188849A1 (en) * 2021-03-11 2022-09-15 InventisBio Co., Ltd. Solid dispersions
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
EP4341260A1 (de) 2021-05-19 2024-03-27 Teva Pharmaceuticals International GmbH Verfahren zur herstellung von sotorasib und festkörperform davon
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023122662A1 (en) 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913491PA (en) 2016-12-22 2020-03-30 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3100390A1 (en) * 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
BR112021008986A2 (pt) 2018-11-09 2021-08-10 F. Hoffmann-La Roche Ag composto, composto da fórmula, composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratar o câncer, para regular a atividade de uma proteína mutante g12c k-ras, para inibir a proliferação de uma população de células, para tratar um distúrbio mediado, para preparar uma proteína e para inibir metástase de tumor e uso
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972967A4 (de) 2019-05-21 2023-07-12 InventisBio Co., Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN111377918B (zh) 2019-11-29 2021-03-02 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
CN111205286B (zh) 2020-01-13 2022-12-13 中科苏州药物研究院 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
US11865115B2 (en) 2024-01-09
US20220226328A1 (en) 2022-07-21
US20240156820A1 (en) 2024-05-16
US20210260067A1 (en) 2021-08-26
CN114846006B (zh) 2024-04-26
EP4077311A1 (de) 2022-10-26
WO2021120045A1 (en) 2021-06-24
JP2023506308A (ja) 2023-02-15
CN118459459A (zh) 2024-08-09
KR20220118478A (ko) 2022-08-25
WO2021121330A1 (en) 2021-06-24
US11241437B2 (en) 2022-02-08
CN114846006A (zh) 2022-08-02
CA3161852A1 (en) 2021-06-24
AU2020410474A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
EP3972967A4 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen
EP4077311A4 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung und ihre verwendungen
EP3889154A4 (de) Zwischenprodukt einer heterozyklischen verbindung, verfahren zu ihrer herstellung und ihre verwendung
EP4015520A4 (de) Sauerstoffhaltige heterocyclische verbindung, verfahren zu ihrer herstellung und ihre verwendung
EP3677583A4 (de) Stickstoffhaltige heterocyclische verbindung, herstellungsverfahren, zwischenprodukt, zusammensetzung und verwendung
EP3424928A4 (de) Stickstoffhaltige heterocyclische verbindung, herstellungsverfahren, zwischenprodukt, zusammensetzung und verwendung
EP3923935A4 (de) Verbindungen, zusammensetzungen und verfahren
EP3599868A4 (de) Herbizidmischung, zusammensetzung und verfahren
EP3917517A4 (de) Verbindungen und verwendungen davon
EP3580208A4 (de) Neuartige heterocyclische verbindung, deren herstellungsverfahren und pharmazeutische zusammensetzung damit
EP3924341A4 (de) Verbindungen, zusammensetzungen und verfahren
EP3632907A4 (de) N-(azaaryl) cyclolactam-1-carboxamid-derivat, herstellungsverfahren dafür und verwendung davon
EP3640248A4 (de) Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon
EP3990445A4 (de) Heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendungen
EP3715342A4 (de) Fluorsulfonylhaltige verbindung, zwischenprodukt davon, herstellungsverfahren dafür und verwendung davon
EP3556761A4 (de) Pyrrolo-aromatische heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon
EP4082534A4 (de) Pharmazeutische zusammensetzung und herstellungsverfahren dafür sowie verwendung davon
EP3858833A4 (de) Aminonordekanderivat und herstellungsverfahren dafür und anwendung davon
EP4006024A4 (de) Heterozyklische amidverbindung, herstellungsverfahren dafür und verwendung davon
EP3952876A4 (de) Heterocyclische verbindungen und verwendungen davon
EP3952875A4 (de) Heterocyclische verbindungen und verwendungen davon
EP3952877A4 (de) Heterocyclische verbindungen und verwendungen davon
EP3828169A4 (de) Dikationsverbindung, herstellungsverfahren dafür und verwendung davon
EP3643311A4 (de) 4-oxo-alkylierte tetramsäureverbindung, herstellungsverfahren dafür und verwendung davon
EP3747870A4 (de) Pyridazinolverbindung, derivat davon, herstellungsverfahren davon, herbizidzusammensetzung und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231025

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20231019BHEP

Ipc: A61K 31/519 20060101ALI20231019BHEP

Ipc: C07D 403/14 20060101ALI20231019BHEP

Ipc: C07D 401/04 20060101ALI20231019BHEP

Ipc: C07D 403/04 20060101AFI20231019BHEP